Q1 2026 Earnings Forecast for Theravance Biopharma, Inc. (NASDAQ:TBPH) Issued By Zacks Research

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for Theravance Biopharma in a research note issued to investors on Monday, April 15th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earnings of $0.29 per share for the quarter, up from their previous estimate of $0.25. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($0.83) per share.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Theravance Biopharma had a negative net margin of 96.12% and a negative return on equity of 19.31%. The business had revenue of $17.57 million during the quarter, compared to analyst estimates of $17.49 million.

TBPH has been the topic of a number of other reports. BTIG Research initiated coverage on Theravance Biopharma in a research report on Friday, April 12th. They set a “buy” rating and a $21.00 target price on the stock. Evercore ISI lowered Theravance Biopharma from an “outperform” rating to an “inline” rating in a research report on Monday, January 8th.

Theravance Biopharma Stock Performance

Shares of TBPH opened at $9.52 on Tuesday. Theravance Biopharma has a 52-week low of $8.21 and a 52-week high of $11.98. The business’s 50 day moving average price is $8.98 and its two-hundred day moving average price is $9.66. The firm has a market cap of $462.29 million, a PE ratio of -9.81 and a beta of 0.36.

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors have recently bought and sold shares of TBPH. Bank of America Corp DE grew its holdings in Theravance Biopharma by 102.4% during the first quarter. Bank of America Corp DE now owns 1,775,966 shares of the biopharmaceutical company’s stock worth $19,269,000 after buying an additional 898,691 shares in the last quarter. Two Sigma Advisers LP bought a new stake in Theravance Biopharma during the third quarter worth $7,064,000. Two Sigma Investments LP bought a new stake in Theravance Biopharma during the third quarter worth $6,620,000. Vanguard Group Inc. grew its holdings in Theravance Biopharma by 10.3% during the first quarter. Vanguard Group Inc. now owns 6,947,947 shares of the biopharmaceutical company’s stock worth $66,421,000 after buying an additional 648,124 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Theravance Biopharma by 184.0% during the first quarter. Goldman Sachs Group Inc. now owns 976,373 shares of the biopharmaceutical company’s stock worth $9,335,000 after buying an additional 632,582 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.